Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

NCT04806451 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Adrenal Hyperplasia

Interventions

DRUG: Crinecerfont
DRUG: Placebo

Sponsor

Neurocrine Biosciences